Stage 2 multiple myeloma is characterized by the presence of a high amount of cancer in the body. All cases of multiple myeloma that don’t fall within stage 1 and stage 3 are considered to be stage 2. Patients with stage 2 multiple myeloma have severe bone complications because of their disease and may require treatment for their symptoms. 

The gradual buildup of myeloma cells can cause fewer blood cells in the bone marrow and damaged bones, along with severe pain and an increased chance of infection. 

There is no cure for stage 2 multiple myeloma, but it is possible to prolong survival by several years using a combination of immunotherapy, stem cell transplantation, and immunotherapy. The only potential cure for multiple myeloma is high-dose therapy followed by stem cell transplantation with donor cells. This treatment has severe side effects and is only used as a last resort in patients who have failed to respond to other treatments [

What are the subtypes of stage 2 Multiple Myeloma?

There are several subtypes of multiple myeloma classified by the type of heavy chains, such as lpG lambda, lgA lambda, lgG kappa, and lgA kappa [

]. The Durie-Salmon staging characterizes stage 2 multiple myeloma by the following factors:

Stage 2 Multiple Myeloma staging and diagnosis

The Durie-Salmon Staging system classifies myeloma in stage 1, stage 2, and stage 3. Myeloma may be further classified into Group A or B depending on the type of damage done to the kidneys. Group A multiple myeloma has not affected the kidneys, while Group B has disrupted kidney function, requiring further treatment.

The international staging system (ISS) is characterized by multiple myeloma based on the albumin level (greater or lesser than 3.5 mg/dL) and B2-microglobulin level. The data for these staging systems comes from over 10,000 cancer outcomes.

According to the American Cancer Society’s Cancer Statistics Center, stage 2 multiple myeloma is relatively uncommon in the United States. About 35,730 new cases will be diagnosed in 2023, with 12,590 deaths. The prevalence of multiple myeloma is 1 in 132 (0.75%), which is highly uncommon [

It is worth noting that stage 2 multiple myeloma is not common in younger individuals. The incidence of the disease increases sharply with increasing age. Multiple myeloma is more common in men over the age of 60. However, most cases of the condition are diagnosed at around 70.

How is stage 2 Multiple Myeloma diagnosed?

It is difficult to diagnose stage 2 multiple myeloma. In general, patients at this stage of multiple myeloma will experience symptoms such as loss of appetite, fatigue, and bone pain, all of which require treatment. Patients will be likely to have MRI scans and CT scans of their arms, skull, spine, and pelvis to look at any signs of damage. 

A more comprehensive diagnosis of stage 2 multiple myeloma will require a bone marrow biopsy. This is done by taking a small sample of bone marrow with the help of a needle. Doctors may also remove a small sample of bone by administering local anesthesia. 

In addition, several tests may be used to confirm the diagnosis, including:

Stage 2 multiple myeloma can cause a wide range of symptoms to indicate disease progression, including:

Treatment for stage 2 multiple myeloma is tailored to the individual patient’s symptoms, risk of myeloma recurrence, and whether they are eligible for stem cell transplant. At stage II, patients will receive treatment with a number of approved medications in an attempt to induce the disappearance of myeloma cells. 

The selection of medication depends on the patient’s risk, age, and overall medical condition. Patients in good health are exposed to more aggressive treatment for complete remission, while older patients may receive less aggressive therapy. Preferred drugs include Velcade, Dexamethasone, and Revlimid. 

Corticosteroids are used to kill myeloma cells and are taken by mouth after eating food. Relapses can be treated if myeloma ever returns. Treatment for relapses is very similar to initial treatment, although non-intensive treatment is often preferred. 

Stage 2 Multiple Myeloma primary/first-line treatment

First-line treatment for stage 2 multiple myeloma involves the use of various drug combinations such as bortezomib, thalidomide, dexamethasone, and daratumumab. After the maximum response to induction therapy, the patient may be prescribed an autologous stem cell transplant (ASCT) after maintenance therapy. 

Targeted therapy also focuses on specific weaknesses found in myeloma cancer cells. Blocking these abnormalities causes cancer cells to die. Some patients continue taking these drugs to keep the myeloma in control. 

Note that the research for stage 2 multiple myeloma is ongoing, with clinical trials comparing new treatments with existing ones to see if the new treatment is more effective. 

Other types of treatment for stage 2 Multiple Myeloma

Besides the first-line treatments for stage 2 multiple myeloma, patients may also need treatment to help relieve the symptoms of the condition, such as:

Secondary treatment for stage 2 multiple myeloma depends on a number of factors, including the patient's age, health, and lifestyle factors. All treatments can cause severe side effects and complications. 

There is no cure for stage 2 multiple, and treatment is aimed at minimizing the symptoms while improving the patient's quality of life. Current therapies, including chemotherapy, proteasome inhibitors, and other medications, are aimed at prolonging the patient's life while minimizing the side effects of medications. 

It is important for patients to regularly follow up with their healthcare team and provide them with blood tests, bone density tests, urine tests, and various imaging studies to monitor disease progression and symptoms of stage 2 multiple myeloma. 

Prognosis: Stage 2 Multiple Myeloma survival rate

Despite the fact that there is no cure for stage 2 multiple myeloma, the disease has a high survival rate, provided that it is caught and treated early. Patients under the age of 50 have a relative survival rate of 76.8%, while those in the age range of 50 to 62 have a survival rate of 67.5%. Meanwhile, the survival rate plummets sharply to 49.6 in patients older than 65. 

Localized myeloma has a higher survival rate of 78.5%. In all cases, additional treatment will be required to prevent a recurrence. 

Research indicates that the 5-year survival rate for people with multiple myeloma in the US is about 55%. Early diagnosis of the disease is important and is attributed to a higher life span. However, the survival rate is only about 54% once cancer has spread to distant parts of the body.

Stage 2 multiple myeloma relapse is very common, according to the International Myeloma Foundation (IMF) [

]. One study found that 16% of patients with multiple myeloma experienced early relapse within a 12-month period. 884% of patients had a relapse after one year or no lapse at the time of the follow-up [

Stage 2 multiple myeloma has a slow growth rate. Researchers found that there is a 73% chance of disease progression in stage 2 multiple myeloma over a 15-year period [

Lifestyle changes for preventing and managing Multiple Myeloma

Although there is no known cure for multiple myeloma, it is important for patients to take care of their health after diagnosis. This includes making regular appointments with the healthcare team and making treatment decisions based on their recommendations.

Here are a few steps that can be taken to prevent and manage the symptoms of stage 2 multiple myeloma.

Stage 2 multiple myeloma is an intermediate stage of cancer that can cause symptoms requiring treatment. Patients diagnosed with this condition should stay on top of their health by closely coordinating with their healthcare team and improving their lifestyle factors. Although there is no cure for multiple myeloma, early treatment and diagnosis can ensure the best possible outcome for patients.

Stage 2 Multiple Myeloma

Other Trials to Consider

STI-1492

Lenalidomide

Dexamethasone

Cevostamab

Cevostamab

DaraVRD

Daratumumab

Radiation Therapy

Lenalidomide

Iberdomide

Popular Categories

Psilocybin Clinical Trials 2024

Hypoglycemia Clinical Trials 2023

Lung Cancer Clinical Trials in Anaheim, CA

Breast Cancer Clinical Trials in Ventura, CA

Parkinson Clinical Trials 2024

Ctcl Clinical Trials 2023

Clinical Trials in Massachusetts

Popular Guides

Learn More About These Treatments

Prefest

Dyazide

Carbidopa

Tolbutamide

Adalat

Aminophyllin

Bydureon Bcise

Rexulti

Bortezomib

Paroxetine Hydrochloride